Cantor Fitzgerald Analysts Give Axsome Therapeutics (AXSM) a $13.00 Price Target
Axsome Therapeutics (NASDAQ:AXSM) has been assigned a $13.00 price target by research analysts at Cantor Fitzgerald in a report released on Friday. The firm presently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 146.68% from the company’s previous close.
Separately, Zacks Investment Research cut Axsome Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $16.70.
Shares of Axsome Therapeutics (AXSM) traded down $0.38 during midday trading on Friday, hitting $5.27. The company had a trading volume of 376,512 shares, compared to its average volume of 177,637. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.86 and a current ratio of 3.86. Axsome Therapeutics has a 52 week low of $3.53 and a 52 week high of $7.20.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.